 "New breast cancer drug may also combat other types of cancer")
A new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy also has potential to fight other types of cancer, new research has found.
Palbociclib targets the rapid division of tumour cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers.
It is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer, researchers said.
"Pairing palbociclib with other anti-cancer therapies such as endocrine therapy, chemotherapy, and targeted therapy can create a powerful combinatorial effect with real promise for addressing a variety of cancers," said Clark.
For example, amplification of CDK4 is reported in a high percentage of melanomas and esophageal cancers.
Targeted therapy uses medication and other interventions to more accurately identify and attack cancer cells, usually while doing no or little damage to normal cells.
"This drug has minor effects on normal cells other than neutrophils (white blood cells)," said the study's senior author, Peter J O'Dwyer, a professor at Penn.
"In tumours, it can cause shrinkage, or more commonly, arrest of growth. As we discover new functions for the CDK4/6 target of this medicine, we are likely to use it in combinations to make other anti-cancer agents work better," said O'Dwyer, also director of the Developmental Therapeutics Programme at the Abramson Cancer Centre (ACC) in US.
In addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.
Assessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumours that while rare, often afflict younger patients.
A phase 2 trial showed that, among 17 patients with previously treated mantle-cell lymphoma, palbociclib resulted in one complete response and two partial responses.
Although, median progression-free survival was four months, five patients had progression-free survival greater than one year.
Another phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66% at 12 weeks, researchers said.
The study was published in the journal JAMA Oncology.
Palbociclib targets the rapid division of tumour cells by inhibiting the activity of the enzymes CDK4 and CDK6, which propel cell division and increase in number in most cancers.
It is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer, researchers said.
More From This Section
"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability," said the study's lead author Amy S Clark, an assistant professor at the University of Pennsylvania.
"Pairing palbociclib with other anti-cancer therapies such as endocrine therapy, chemotherapy, and targeted therapy can create a powerful combinatorial effect with real promise for addressing a variety of cancers," said Clark.
For example, amplification of CDK4 is reported in a high percentage of melanomas and esophageal cancers.
Targeted therapy uses medication and other interventions to more accurately identify and attack cancer cells, usually while doing no or little damage to normal cells.
"This drug has minor effects on normal cells other than neutrophils (white blood cells)," said the study's senior author, Peter J O'Dwyer, a professor at Penn.
"In tumours, it can cause shrinkage, or more commonly, arrest of growth. As we discover new functions for the CDK4/6 target of this medicine, we are likely to use it in combinations to make other anti-cancer agents work better," said O'Dwyer, also director of the Developmental Therapeutics Programme at the Abramson Cancer Centre (ACC) in US.
In addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.
Assessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumours that while rare, often afflict younger patients.
A phase 2 trial showed that, among 17 patients with previously treated mantle-cell lymphoma, palbociclib resulted in one complete response and two partial responses.
Although, median progression-free survival was four months, five patients had progression-free survival greater than one year.
Another phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66% at 12 weeks, researchers said.
The study was published in the journal JAMA Oncology.